Mast cells: Bridging the gap between pre- and post-capillary pulmonary hypertension?

European Respiratory Journal

Volumn 37, Issue 6, 2011, Pages 1303-1305

  Montani, D ^a   Lang, I M ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENIC AMINE; HISTAMINE; IMATINIB; INTERLEUKIN 3; PROTEIN TYROSINE KINASE; SEROTONIN; SORAFENIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANGIOGENESIS; CELL PROLIFERATION; DISEASE MODEL; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HEART DISEASE; HUMAN; HYDROSTATIC PRESSURE; HYPOXIA; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MAST CELL; NONHUMAN; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULMONARY VEIN; SMOOTH MUSCLE FIBER; VASOCONSTRICTION;

ANIMALS; CAPILLARIES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MAST CELLS; PULMONARY HEART DISEASE; RATS;

EID: 79958005962     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00033611     Document Type: Editorial

References (29)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493-2537.
3. Lipman J. Pitfalls in the interpretation of pulmonary capillary wedge pressure. S Afr Med J 1985; 67: 174-177. (Pubitemid 15143827)
4. Tonelli AR, Mubarak KK, Li N, et al. Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension. Chest 2011; 139: 115-121.
5. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
6. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54. (Pubitemid 27329022)
7. Buchbinder N, Ganz W. Hemodynamic monitoring: invasive techniques. Anestesiology 1976; 45: 146-155.
8. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183-188. (Pubitemid 32051736)
9. Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009; 119: 2663-2670.
10. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119-1126.
11. 2+ signaling and cytoskeletal reorganization. Circ Res 2010; 106: 1103-1116.
12. Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 2011; 37: 1400-1410.
13. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073. (Pubitemid 19231814)
14. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension - from bench to bedside? Curr Opin Pharmacol 2009; 9: 281-286.
15. Bankl HC, Radaszkiewicz T, Klappacher GW, et al. Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand. Circulation 1995; 91: 275-283.
16. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
17. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63: 213-224.
18. Bischoff SC, Dahinden CA. c-Kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992; 175: 237-244.
19. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991; 44: 1003-1006.
20. Davie NJ, Crossno JT Jr, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L668-L678. (Pubitemid 38365049)
21. Crossno JT Jr, Garat CV, Reusch JE, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007; 292: L885-L897. (Pubitemid 46608235)
22. Montani DPF, Perros F, Gambaryan N, et al. c-Kit positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; [Epub ahead of print DOI: 10.1164/rccm.201006- 200905OC].
23. Banasova A, Maxova H, Hampl V, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008; 76: 102-107. (Pubitemid 351914146)
24. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821. (Pubitemid 41434408)
25. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118: 2081-2090.
26. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008; 33: 278-291. (Pubitemid 351629535)
27. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
28. Gambaryan N, Perros F, Montani D, et al. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. Eur Respir J 2010; 36: 1209-1211.
29. Gambaryan N, Perros F, Montani D, et al. Targeting of c-kit+ hematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J 2010; [Epub ahead of print DOI: 10.1183/09031936.00045710].